Table 4.
Multivariable Cox proportional hazards model of predictors of mortality in young women with endometrial carcinoma by stage
| Overall cohort HR (95%CI) | Stage IA HR (95%CI) | Stage IB HR (95%CI) | Stage INOS HR (95%CI) | |
|---|---|---|---|---|
| Hormonal therapy | ||||
| No | Referent | Referent | Referent | Referent |
| Yes | 1.92 (1.15–3.19)* | 1.20 (0.53–2.68) | 3.52 (1.57–7.90)* | 3.91 (1.41–10.82)* |
| Age | ||||
| <35 | Referent | Referent | Referent | Referent |
| 35–39 | 1.23 (0.78–1.92) | 1.11 (0.70–1.77) | 3.61 (0.99–13.23) | 0.52 (0.15–1.81) |
| 40–44 | 1.55 (1.04–2.31)* | 1.44 (0.92–2.26) | 1.91 (0.52–7.06) | 1.52 (0.58–3.93) |
| 45–49 | 2.05 (1.39–3.03)* | 1.71 (1.09–2.69)* | 4.92 (1.44–16.77)* | 1.87 (0.76–4.63) |
| Race | ||||
| White | Referent | Referent | Referent | Referent |
| Black | 1.32 (0.96–1.82) | 1.12 (0.80–1.56) | 0.63 (0.23–1.75) | 3.18 (1.63–6.21)* |
| Hispanic | 0.74 (0.53–1.02) | 0.75 (0.50–1.12) | 0.56 (0.20–1.53) | 0.67 (0.23–1.96) |
| Other | 0.53 (0.31–0.91)* | 0.55 (0.28–1.07) | 0.18 (0.02–1.49) | 0.95 (0.29–3.12) |
| Unknown | 1.45 (1.03–2.02)* | 1.12 (0.77–1.64) | 1.64 (0.87–3.07) | 2.44 (1.28–4.66)* |
| Insurance Status | ||||
| Private Insurance | Referent | Referent | Referent | Referent |
| Medicaid | 2.44 (1.86–3.21)* | 2.39 (1.78–3.22)* | 1.60 (0.75–3.37) | 3.00 (1.62–5.58)* |
| Medicare | 3.08 (2.16–4.40)* | 3.22 (2.07–5.03)* | 2.94 (1.59–5.45)* | 3.78 (1.64–8.73)* |
| Not Insured | 1.41 (1.02–1.96)* | 1.53 (1.03–2.27)* | 1.59 (0.68–3.73) | 0.82 (0.23–2.94) |
| Other/Unknown | 2.29 (1.37–3.82)* | 1.40 (0.79–2.49) | 3.29 (1.34–8.06)* | 2.95 (1.08–8.04)* |
| Median Income | ||||
| < $30,000 | Referent | Referent | Referent | Referent |
| $30,000 – $35,999 | 0.85 (0.62–1.18) | 0.82 (0.58–1.15) | 0.66 (0.31–1.43) | 0.89 (0.37–2.14) |
| $36,000 – $45,999 | 0.91 (0.68–1.23) | 0.73 (0.54–1.00)* | 1.01 (0.52–1.98) | 1.42 (0.65–3.11) |
| $46,000 + | 0.66 (0.47–0.93)* | 0.58 (0.39–0.85)* | 0.55 (0.27–1.12) | 1.31 (0.52–3.30) |
| Unknown | 0.80 (0.48–1.35) | 0.75 (0.44–1.29) | 1.90 (0.63–5.72) | 0.14 (0.01– .23) |
| Urban/Rural | ||||
| Metropolitan | Referent | Referent | Referent | Referent |
| Urban | 0.96 (0.75–1.24) | 0.96 (0.69–1.32) | 1.22 (0.70–2.14) | 0.88 (0.44–1.76) |
| Rural | 1.27 (0.79–2.02) | 1.45 (0.87–2.41) | 0.95 (0.23–3.87) | 0.85 (0.15–4.80) |
| Unknown | 1.38 (0.91–2.10) | 1.38 (0.84–2.29) | 2.24 (0.84–5.97) | 1.12 (0.23–5.54) |
| Comorbidity Score | ||||
| 0 | Referent | Referent | Referent | Referent |
| 1 | 1.79 (1.37–2.34)* | 1.64 (1.23–2.19)* | 1.67 (0.99–2.83) | 2.32 (1.19–4.52)* |
| 2 | 2.60 (1.87–3.63)* | 2.08 (1.39–3.09)* | 3.26 (1.52–7.01)* | 5.56 (2.72–1.40)* |
| Year of diagnosis | 0.98 (0.93–1.04) | 0.96 (0.91–1.02) | 1.07 (0.97–1.19) | 0.99 (0.83–1.17) |
| Stage | ||||
| IA | Referent | NA | NA | NA |
| IB | 2.49 (1.77–3.50)* | NA | NA | NA |
| INOS | 1.29 (0.92–1.82) | NA | NA | NA |
| Grade | ||||
| 1 | Referent | Referent | Referent | Referent |
| 2 | 1.41 (1.09–1.81)* | 3.33 (2.25–4.93)* | 0.98 (0.58–1.66) | 1.57 (0.66–3.76) |
| 3 | 2.79 (2.00–3.87)* | 1.49 (1.14–1.94)* | 1.74 (0.96–3.17) | 2.82 (0.99–8.08) |
| Unknown | 1.14 (0.77–1.70) | 1.24 (0.80–1.92) | 0.87 (0.40–1.87) | 0.77 (0.28–2.11) |
| Histology | ||||
| Endometrioid | Referent | Referent | Referent | Referent |
| EM_NOS | 0.87 (0.67–1.14) | 0.94 (0.70–1.28) | 1.19 (0.66–2.17) | 0.53 (0.23–1.23) |
Cohort derived from propensity score using inverse probability of treatment weighting. #Year of diagnosis was fit as continuous variable in multivariable regression model.
*
P<0.05